Floatz logo

89zr-dfo-n-suc-c9scfv

Esophageal Carcinoma

Var2 PharmaceuticalsradiopharmaceuticalEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

40 Active assets in the Esophageal Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
NuCana plc
Phase 3BB
Docetaxel
NuCana plc
Phase 3BB
Irinotecan
Merck Sharp & Dohme LLC
Phase 3B
TRASTUZUMAB
National Cancer Institute (NCI)
Phase 2CCC
Palbociclib
National Cancer Institute (NCI)
Phase 2CCC

View all 50 →

Same molecule, other indications

89zr-dfo-n-suc-c9scfv is also rated in:

colon carcinomaDormant
C
Indicative ·
39 / 100
View asset →
rectal carcinomaDormant
C
Indicative ·
39 / 100
View asset →
chondrosarcomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →